JP6563937B2 - 寛容原性組成物およびその使用 - Google Patents

寛容原性組成物およびその使用 Download PDF

Info

Publication number
JP6563937B2
JP6563937B2 JP2016549420A JP2016549420A JP6563937B2 JP 6563937 B2 JP6563937 B2 JP 6563937B2 JP 2016549420 A JP2016549420 A JP 2016549420A JP 2016549420 A JP2016549420 A JP 2016549420A JP 6563937 B2 JP6563937 B2 JP 6563937B2
Authority
JP
Japan
Prior art keywords
vaca
pylori
allergen
pharmaceutical composition
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509597A (ja
JP2017509597A5 (OSRAM
Inventor
ミュラー、アンヌ
エングラー−アンデルス、ダニエラ
タウベ、クリスティアン
Original Assignee
ユニヴァーシテト チューリッヒ
ユニヴァーシテト チューリッヒ
ライデン ユニバーシティ メディカル センター
ライデン ユニバーシティ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシテト チューリッヒ, ユニヴァーシテト チューリッヒ, ライデン ユニバーシティ メディカル センター, ライデン ユニバーシティ メディカル センター filed Critical ユニヴァーシテト チューリッヒ
Publication of JP2017509597A publication Critical patent/JP2017509597A/ja
Publication of JP2017509597A5 publication Critical patent/JP2017509597A5/ja
Application granted granted Critical
Publication of JP6563937B2 publication Critical patent/JP6563937B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016549420A 2014-01-31 2015-01-30 寛容原性組成物およびその使用 Active JP6563937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14153365.3A EP2902037A1 (en) 2014-01-31 2014-01-31 Tolerogenic compositions comprising and uses thereof
EP14153365.3 2014-01-31
PCT/IB2015/050703 WO2015114575A1 (en) 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof

Publications (3)

Publication Number Publication Date
JP2017509597A JP2017509597A (ja) 2017-04-06
JP2017509597A5 JP2017509597A5 (OSRAM) 2018-03-01
JP6563937B2 true JP6563937B2 (ja) 2019-08-21

Family

ID=50028895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549420A Active JP6563937B2 (ja) 2014-01-31 2015-01-30 寛容原性組成物およびその使用

Country Status (8)

Country Link
US (1) US9999660B2 (OSRAM)
EP (2) EP2902037A1 (OSRAM)
JP (1) JP6563937B2 (OSRAM)
AU (1) AU2015212357B2 (OSRAM)
CA (1) CA2943149C (OSRAM)
DK (1) DK3099314T3 (OSRAM)
ES (1) ES2806773T3 (OSRAM)
WO (1) WO2015114575A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166986B2 (en) 2014-01-31 2021-11-09 Universitat Zurich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4669337A1 (en) * 2023-09-26 2025-12-31 Atopia Therapeutics Sa USEFUL AGENTS FOR THE PREVENTION OR TREATMENT OF ALLERGIC AND INFAMMATORY DISORDERS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004017A2 (en) * 2000-07-07 2002-01-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for preparing oral vaccines
JP2005506322A (ja) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
JP2004189730A (ja) * 2002-11-28 2004-07-08 Japan Science & Technology Agency 細胞死の抑制方法、細胞死抑制剤、及びその細胞死抑制剤を含む細胞死に起因する疾患の治療薬剤
US11166986B2 (en) 2014-01-31 2021-11-09 Universitat Zurich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease

Also Published As

Publication number Publication date
EP2902037A1 (en) 2015-08-05
AU2015212357B2 (en) 2020-05-28
EP3099314B1 (en) 2020-04-22
EP3099314A1 (en) 2016-12-07
ES2806773T3 (es) 2021-02-18
DK3099314T3 (da) 2020-07-20
US20170007683A1 (en) 2017-01-12
WO2015114575A1 (en) 2015-08-06
JP2017509597A (ja) 2017-04-06
US9999660B2 (en) 2018-06-19
CA2943149A1 (en) 2015-08-06
CA2943149C (en) 2022-07-12
AU2015212357A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
RS58121B1 (sr) Kompozicije koje sadrže bakterijske sojeve
ES2345188T3 (es) Preparaciones de bacterias gram positivas para el tratamiento de enfermedades que comprenden una mala regulacion inmune.
ES2352780B2 (es) Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
KR101469167B1 (ko) 봉독-ｐｌａ2를 포함하는 이상 조절 ｔ 세포 활성 저하 관련 질환의 치료 또는 예방용 약학적 조성물
JP2011157380A (ja) 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
JP6563937B2 (ja) 寛容原性組成物およびその使用
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
JP2015506975A (ja) 家畜の非ヒト哺乳動物における炎症性疾患の予防
JPWO1999040935A1 (ja) 新規な免疫異常性疾患予防・治療用剤
US11166986B2 (en) Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
JP7393007B2 (ja) 免疫寛容誘導剤及びアレルギー性疾患の治療又は予防剤
JP2025521110A (ja) 食物アレルギーを予防または治療するための方法および組成物
AU2004279209A1 (en) Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
CN110573179A (zh) 包含弱毒化的肺炎链球菌菌株的药剂学组合物及其用途
US20090162324A1 (en) Use of Whole Cell Actinomycetales Bacteria to Treat Stress-Induced Pulmonary Haemorrhage
US9289485B2 (en) Therapeutic application of S. pyogenes C-terminal peptide
JP2013090574A (ja) ペプチドワクチン
JP2009533478A (ja) 黄色ブドウ球菌感染症の治療用薬剤の製造のための活性成分としてｔｒａｐタンパク質自体の使用
Chi-Yan Development of a mouse model of shrimp allergy
KR20190108352A (ko) 약독화된 폐렴구균 균주를 포함하는 약제학적 조성물 및 이의 용도
Mills et al. Whole-Cell but Not Acellular Pertussis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190725

R150 Certificate of patent or registration of utility model

Ref document number: 6563937

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250